These include recommending annual mammograms and MRI screenings of the remaining breast tissue for BRCA1/2 mutation carriers, or risk-reducing surgeries to prevent contralateral BC in BRCA1/2 PV-carriers8,18, use of mastectomy rather than lumpectomy with radiotherapy for BC patients with PVs in TP5319, and utilizing risk-reducing salpingo-oophorectomy for BRCA1/2, BRIP1, and RAD51 C/D- carrying patients as a preventive approach of subsequent ovarian cancer development, due to its increased association with these PVs8,20,21. This evidence concerns the gene BRCA1 and ovarian carcinoma.